Placebo to empagliflozin

DRUG2 trials

Sponsors

Boehringer Ingelheim

Conditions

Heart FailureKidney Disease, Chronic

Phase 2

A Study to Test Whether Different Doses of BI 690517 Alone or in Combination With Empagliflozin Improve Kidney Function in People With Chronic Kidney Disease

CompletedNCT05182840

Boehringer IngelheimKidney Disease, Chronic

Start: 2022-01-11End: 2023-07-10Updated: 2024-10-22

Phase 3

A Study to Test the Effect of Empagliflozin in Patients Who Are in Hospital for Acute Heart Failure

CompletedNCT04157751

Boehringer IngelheimHeart Failure

Start: 2020-05-18End: 2021-06-02Updated: 2022-07-19

Related Papers

Pharmacodynamics of vicadrostat for aldosterone synthase inhibition in patients with CKD.

2026-01-01

#3201 Effects of vicadrostat with and without empagliflozin in people with chronic kidney disease by baseline BMI

Nephrology Dialysis Transplantation2025-10-01

#3315 Vicadrostat with and without empagliflozin reduces albuminuria across KDIGO risk class in chronic kidney disease

Nephrology Dialysis Transplantation2025-10-01

Systolic plood pressure response to ASi BI 690517 with and without empagliflozin in CKD

European Heart Journal2024-10-011 citations

Time from Admission to Randomization and the Effect of Empagliflozin in Acute Heart Failure: A Post-Hoc Analysis from EMPULSE

European Journal of Heart Failure2024-07-095 citations

#1418 Phase II dose-selection, randomised, controlled trial of ASi BI 690517 with and without EMPA in CKD: subgroup analysis by T2D status

Nephrology Dialysis Transplantation2024-05-011 citations

Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial.

2023-12-15100 citations

Methods Article for a Study Protocol: Study Design and Baseline Characteristics for Aldosterone Synthase Inhibition in Chronic Kidney Disease

American Journal of Nephrology2023-10-3015 citations

Mineralocorticoid Receptor Antagonist Use and the Effects of Empagliflozin on Clinical Outcomes in Patients Admitted for Acute Heart Failure: Findings from EMPULSE

European Journal of Heart Failure2023-08-0416 citations

#3318 PHASE II DOSE-SELECTION, RANDOMISED DOUBLE-BLIND TRIAL OF THE ASI, BI 690517, ALONE AND IN COMBINATION WITH EMPA IN PEOPLE WITH CKD

Nephrology Dialysis Transplantation2023-06-012 citations

The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial.

2022-02-28550 citations

Early Initiation of SGLT2 Inhibitors is Important, Irrespective of Ejection Fraction: SOLOIST-WHF in Perspective

ESC Heart Failure2020-12-0128 citations